Cartesian Therapeutics Announces New Employment Inducement Grant
The employee option carries a $6.34 exercise price, matching the stock’s closing trading price on the grant date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cartesian Therapeutics (RNAC) granted a new employee an option to purchase 50,000 common shares on November 2, 2026. The exercise price is $6.34, matching the closing trading price on the grant date. The option vests 25% on November 2, 2027, with the remainder vesting in thirty-six substantially equal monthly installments through November 2, 2030.
The board-approved award has a ten-year term and was granted under the Amended and Restated 2018 Employment Inducement Incentive Award Plan. It was an employment inducement under Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.50,000-share employee option at a $6.34 exercise price creates potential dilution upon exercise.
Key Figures
- Options granted
- 50,000 shares
- Inducement award to one new employee
- Exercise price
- $6.34 per share
- Equal to the closing trading price on the grant date
- Initial vesting
- 25%
- Vests on November 2, 2027
- Subsequent vesting
- 36 substantially equal monthly installments
- Following the initial vesting
- Option term
- 10 years
- Term of the inducement option
Historical Context
-
Prior grant covered 121,900 options for four new employees, with a ten-year term and similar vesting structure.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREDERICK, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On November 2, 2026, the Company issued to this employee an option to purchase an aggregate of 50,000 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Cartesian Therapeutics’ new employee option grant?
The employee received an option to purchase 50,000 common shares at $6.34 per share on November 2, 2026. The exercise price matched the closing trading price on the grant date, and the option has a ten-year term.
When does Cartesian Therapeutics’ November 2026 employee option vest?
The option vests 25% on November 2, 2027, followed by thirty-six substantially equal monthly installments. It will be fully vested on November 2, 2030.